The Enhanced Liver Fibrosis (ELF) is the first prognostic tool for patients with advanced fibrosis (F3 or F4) due to non-alcoholic steatohepatitis (NASH) to be granted De Novo marketing authorization.

At present, transient elastography and the serum marker FibroTest are the most intensively evaluated non-invasive methods for the assessment of liver fibrosis. The results of the present study for ...

The Enhanced Liver Fibrosis (ELF) Test from Siemens Healthineers is now available in the United States, providing broad clinical access to the minimally invasive prognostic tool. Currently, the ELF ...

Enhanced Liver Fibrosis (ELF™) Test Gauges Likelihood of Disease Progression; Expands Labcorp’s Testing Options for Nonalcoholic Fatty Liver Disease The ELF test provides a numeric score to people ...

Siemens is launching a new diagnostic amid a rise in liver damage cases caused by so-called fatty-liver disease. (Database Center for Life Science/CC BY-SA 2.1) () Siemens is launching its Enhanced ...

Siemens has developed a new test for diagnosing liver damage that requires only a blood sample instead of a biopsy. The Enhanced Liver Fibrosis test is not only less invasive and painful than the ...

BURLINGTON, N.C.--(BUSINESS WIRE)--For the millions of people in the United States living with an advanced form of chronic liver disease, simply understanding the potential for future complications ...

Background: FibroTest (FT) is the most frequently used serum fibrosis marker and consists of an algorithm of five fibrosis markers (alfa2-macroglobulin, apolipoproteinA1, haptoglobin, GGT, bilirubin).